Stock Market Update: Key Insights for Trading on March 17
The NSE Nifty 50 ended 0.33 percent lower at 22,397.20 The BSE Sensex was 0.27 percent lower to 73,828.9 in the course of Thursday.
Stock Market Update: Key Insights for Trading on March 17

Asian stocks rose as China has pledged to take more measures to increase consumption and US markets closed higher. Japan's Nikkei increased by 1.3 percent, while the Australian S&P ASX 200 gained 0.6 percent, as South Korea's Kospi increased by 1.5 1.5%.
The futures market on the Indian Share market today were up 1.8 percent.. In the US the S&P 500 rose 2.13 percent in the final hour to 5,638.94 The Dow Jones rose 1.65% to 41,488.19 while The Nasdaq Composite surged 2.61% to 17,754.
Stocks To Watch
IndusInd Bank Ltd: HDFC Mutual Funds Total stake in IndusInd Bank has exceeded 5 percent, prompting the NSE to put IndusInd Bank shares under short-term additional monitoring procedures (Stage 1,).
Ola Electric Mobility: Rosmerta Digital Services seeks to commence insolvency proceedings against a Ola Electric subsidiary, alleging the company is in default on the payment of registration fees for vehicles that were provided
Alkem Laboratories: The USFDA did not issue a Form 483 after the bioresearch monitoring audit at the centre for bioequivalence in Maharashtra.
3M India: The company's board has approved the appointment of Nikhil Arora as chief financial officer, effective May 5.
Dalmia Bharat: The firm began commercial production of a the new grinding unit that has 2.4 MTPA at Lanka, Assam.
Zydus Lifescience: The company was granted USFDA approbation in the form of Eluxadoline Tablets. The tablets treat irritable bowel syndrome by treating diarrhoea. Eluxadoline tablets sold an annual revenue in the range of %243.7 million across the US.
Infosys Company had settled six class action litigations filed against its US company in exchange for $17.5 million. These suits relate to a breach of cybersecurity in the month of November 2023 which exposed the personal information of 6
Shilpa Medicare: Shilpa Medicare Raichur unit is now completing their second successive USFDA inspection without making any observations.